CliffBio
biologic

Prolia

denosumab

Loss of exclusivityJune 2022projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameProlia
Active ingredientdenosumab
Strength60MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2010
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Prolia patent cliff — loss of exclusivity June 2022 | CliffBio